Samumed Initiates Phase 1b Trial of SM04755 for Treatment of Psoriasis
October 31, 2017 08:00 ET | SAMUMED
- Top-line data expected by Q2 2018 - SAN DIEGO, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Samumed, LLC, today announces the enrollment of the first psoriasis patient in its Phase 1b trial of SM04755, a...
Samumed Announces 52-week Phase 2 Osteoarthritis Data Supporting the Potential of SM04690 as a Disease Modifying Drug
October 24, 2017 08:00 ET | SAMUMED
- SM04690 exhibited clinically meaningful and significant improvements in pain, function, and joint space width in unilateral symptomatic osteoarthritis patients - - Samumed will be presenting data...